AR101728A1 - Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas - Google Patents
Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismasInfo
- Publication number
- AR101728A1 AR101728A1 ARP150102789A ARP150102789A AR101728A1 AR 101728 A1 AR101728 A1 AR 101728A1 AR P150102789 A ARP150102789 A AR P150102789A AR P150102789 A ARP150102789 A AR P150102789A AR 101728 A1 AR101728 A1 AR 101728A1
- Authority
- AR
- Argentina
- Prior art keywords
- doxylamine
- component
- active ingredient
- piridoxine
- metabolites
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Forma de dosificación oral sólida que comprende un núcleo que comprende un componente de doxilamina y un componente de piridoxina revestido con un revestimiento entérico. La forma de dosificación oral sólida comprende además dos revestimientos que contienen ingrediente activo que rodean el revestimiento entérico, los revestimientos que contienen ingrediente activo se separan uno del otro por un revestimiento intermedio, y uno de los dos revestimientos contiene ingrediente activo que comprende un componente de doxilamina y está libre de un componente de piridoxina, y el otro de los dos revestimientos contiene ingrediente activo que comprende un componente de piridoxina y está libre de componente de doxilamina. Usos de la forma de dosificación oral sólida para el alivio de los síntomas de náuseas y vómito, por ejemplo en el caso de náuseas y vómito del embarazo (NVP).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CA2014/050828 WO2016029290A1 (en) | 2014-08-29 | 2014-08-29 | Plurimodal release formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR101728A1 true AR101728A1 (es) | 2017-01-11 |
Family
ID=55398524
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150102789A AR101728A1 (es) | 2014-08-29 | 2015-08-31 | Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP3185856B1 (es) |
| JP (1) | JP6272561B2 (es) |
| KR (1) | KR101831570B1 (es) |
| CN (1) | CN106794148B (es) |
| AR (1) | AR101728A1 (es) |
| AU (1) | AU2014405049B2 (es) |
| CA (1) | CA2920247C (es) |
| CY (1) | CY1120788T1 (es) |
| DK (1) | DK3185856T3 (es) |
| EA (1) | EA032671B1 (es) |
| ES (1) | ES2674996T3 (es) |
| FR (1) | FR24C1000I1 (es) |
| HU (1) | HUE038969T2 (es) |
| IL (1) | IL250541B (es) |
| MX (1) | MX360662B (es) |
| MY (1) | MY196073A (es) |
| PH (1) | PH12017500282A1 (es) |
| PL (1) | PL3185856T3 (es) |
| PT (1) | PT3185856T (es) |
| SA (1) | SA517380942B1 (es) |
| SG (1) | SG11201701448XA (es) |
| TR (1) | TR201809565T4 (es) |
| UA (1) | UA118711C2 (es) |
| WO (1) | WO2016029290A1 (es) |
| ZA (1) | ZA201701063B (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3628311T (pt) | 2018-09-27 | 2021-02-09 | Inibsa Ginecologia S A | Um processo para a preparação de uma forma de dosagem oral, de unidade múltipla de libertação modificada, de sucinato de doxilamina e cloridrato de piridoxina |
| AR121619A1 (es) | 2020-03-25 | 2022-06-22 | Inibsa Ginecologia S A | Una forma de dosificación oral de múltiples unidades de liberación modificada de succinato de doxilamina y clorhidrato de piridoxina y un procedimiento para su preparación |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| CA2350195C (en) * | 2000-12-20 | 2003-06-10 | Duchesnay Inc. | Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate |
| TWI292138B (en) * | 2004-03-11 | 2008-01-01 | Mstar Semiconductor Inc | Device for adaptively adjusting video's luminance and related method |
| ES2452019T5 (es) * | 2004-11-05 | 2021-06-28 | Boehringer Ingelheim Int | Comprimido bicapa que comprende telmisartán y amlodipino |
| WO2010107971A1 (en) * | 2009-03-20 | 2010-09-23 | Novartis Ag | Galenical formulations of a fixed dose combination of valsartan and aliskiren |
| EP2500016A1 (en) * | 2011-03-18 | 2012-09-19 | Laboratorios Del. Dr. Esteve, S.A. | Doxylamine resinate complex |
| CA2761212A1 (en) * | 2011-12-07 | 2013-06-07 | Pharmascience Inc. | Disintegrant-free delayed release doxylamine and pyridoxine formulation and process of it manufacturing |
| WO2013123569A1 (en) * | 2012-02-22 | 2013-08-29 | Duchesnay Inc. | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
| SG11201403931YA (en) * | 2012-02-22 | 2014-08-28 | Duchesnay Inc | Formulation of doxylamine and pyridoxine and/or metabolites or salts thereof |
-
2014
- 2014-08-29 SG SG11201701448XA patent/SG11201701448XA/en unknown
- 2014-08-29 MY MYPI2017700682A patent/MY196073A/en unknown
- 2014-08-29 ES ES14900963.1T patent/ES2674996T3/es active Active
- 2014-08-29 EP EP14900963.1A patent/EP3185856B1/en active Active
- 2014-08-29 HU HUE14900963A patent/HUE038969T2/hu unknown
- 2014-08-29 KR KR1020177008120A patent/KR101831570B1/ko active IP Right Grant
- 2014-08-29 PT PT14900963T patent/PT3185856T/pt unknown
- 2014-08-29 AU AU2014405049A patent/AU2014405049B2/en active Active
- 2014-08-29 UA UAA201702935A patent/UA118711C2/uk unknown
- 2014-08-29 JP JP2017511764A patent/JP6272561B2/ja active Active
- 2014-08-29 PL PL14900963T patent/PL3185856T3/pl unknown
- 2014-08-29 EA EA201790477A patent/EA032671B1/ru unknown
- 2014-08-29 CA CA2920247A patent/CA2920247C/en active Active
- 2014-08-29 TR TR2018/09565T patent/TR201809565T4/tr unknown
- 2014-08-29 CN CN201480081512.3A patent/CN106794148B/zh active Active
- 2014-08-29 MX MX2017002495A patent/MX360662B/es active IP Right Grant
- 2014-08-29 WO PCT/CA2014/050828 patent/WO2016029290A1/en active Application Filing
- 2014-08-29 DK DK14900963.1T patent/DK3185856T3/en active
-
2015
- 2015-08-31 AR ARP150102789A patent/AR101728A1/es not_active Application Discontinuation
-
2017
- 2017-02-09 IL IL250541A patent/IL250541B/en active IP Right Grant
- 2017-02-13 ZA ZA201701063A patent/ZA201701063B/en unknown
- 2017-02-15 PH PH12017500282A patent/PH12017500282A1/en unknown
- 2017-02-21 SA SA517380942A patent/SA517380942B1/ar unknown
-
2018
- 2018-08-10 CY CY20181100842T patent/CY1120788T1/el unknown
-
2024
- 2024-01-04 FR FR24C1000C patent/FR24C1000I1/fr active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP18040250A (es) | Composiciones y métodos para inhibir la actividad arginasa | |
| DOP2020000102A (es) | Compuestos útiles para inhibir a cdk7 | |
| CL2018002334A1 (es) | Moduladores de complementos factor b (divisional solicitud 201600606) | |
| CO2017001994A2 (es) | Compuestos activos hacia bromodominios | |
| BR112017007123A2 (pt) | derivados de tetrahidroisoquinolina | |
| BR112018010720A8 (pt) | agonistas do receptor de apelina e métodos de uso | |
| UY36275A (es) | Compuestos aminopirimidinilo | |
| SV2016005137A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| CR20180564A (es) | Nuevos derivados piperidinilo, un proceso para su preparación y composiciones farmacéuticas que lo contienen | |
| BR112016024631A2 (pt) | cápsulas antimicrobianas para conectores médicos | |
| BR112016024057A2 (pt) | inibidores de quinases heterocíclicos | |
| CL2015002608A1 (es) | Compuesto de amino-pirazol y usos medicinales relacionados. | |
| DK3582780T3 (da) | Aminopyrimidinforbindelser, der er anvendelige som SSAO-inhibitorer | |
| BR112018072539A2 (pt) | composições de epinefrina de administração aumentada | |
| GT201700023A (es) | Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias | |
| BR112016024539A8 (pt) | Combinador óptico ativo para rede catv | |
| CR20160192A (es) | Formulación de farmaco de liberación retardada | |
| BR112017026655A2 (pt) | dispositivo de comunicação e rede que usam protocolo tdma de radiocomunicação | |
| CR20180089A (es) | Compuestos útiles para inhibir a ror-gamma-t | |
| BR112017004948A2 (pt) | formulação farmacêutica. | |
| BR112018070615A2 (pt) | formulação em grânulos contendo cloridrato de cariprazina para administração oral. | |
| AR101728A1 (es) | Formulación de liberación plurimodal de doxilamina y piridoxina y/o metabolitos o sales de las mismas | |
| MX2020004202A (es) | Fenil sulfonil fenil triazol tionas sustituidas y usos de las mismas. | |
| CL2018001157A1 (es) | Formulación de combinación de dosis fija, eflornitina y sulindaco. | |
| CO2020003134A2 (es) | Moduladores de la expresión de enac |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |